Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
OssDsign is a developer and supplier of orthobiological products. The company develops and markets products that support the body's own healing ability, such as OssDsign Catalyst, which is a nanosynthetic bone graft for dual bone formation pathways through fusion mass. The company offers its products around the global market. OssDsign was founded in 2011 and is headquartered in Uppsala.
* Transition of US sales team to drive a turnaround in sales generation * No change to mid-term targets * Fair value range revised down to SEK 3.1-5.1 (3.2-5.4) Miss on sales, but opex better in Q3 Q3 marked another quarter with soft sales momentum but...
* 42% beat (less negative) on adj EBIT but miss on sales * -20% organic growth (ABGSCe -18%) * No change in outlook Q3 results OssDsign reported a mixed set of numbers in Q3 with 3% lower sales, gross margin in line, but good cost control on opex resulting...
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
* We expect soft sales momentum for Q3e * Negative earnings revisions on lower sales * Q3'26 results due 3 November Q3'26 expectations We do not expect to see any major change in OssDsign's sales development in Q3e, compared with previous quarters during...
* Expected return to growth pushed out to Q4 * Adj. EBIT cut by 2.6%-3.6% for '26e-'28e * Fair value range revised down to SEK 3.8-6.2 (4.0-6.3) Small miss on sales, but lower opex in Q2 OssDsign reported mixed results in Q2: sales were 1% below expectations...
* 10% beat on adj EBIT but lower saIes * -16% organic growth (ABGSCe -15%) * No change in outlook, Q3 seasonally soft Q2 results OssDsign reported a mixed set of numbers in Q2 with 1% lower sales, lower gross margin, but good cost control on opex resulting...
* Sequentially flattish, but -15% organic drop in sales in Q2e * We assume a recovery in sales growth in H2'26e * Q2'26 results due 18 August Q2'26 expectations We expect sales development to have stabilised in Q2, at a similar level to Q1'26, but lower...
* Q1 in line with pre-announced numbers * Minor estimate revisions, H2'26 the key catalyst * Fair value range unchanged at SEK 4.0-6.2 Weak GM in Q1, opex offset Q1 sales confirmed the pre-announced number of SEK 36.9m (0% vs. ABGSCe) with an organic...